Christine Mikail

Ms. Mikail has almost two decades of experience supporting biotechnology and pharmaceutical companies in legal, business development, operations and finance capacities. Most recently, she co-founded Neumentum, Inc., a neurology specialty pharma company, and Ferndale Advisors, a consulting firm advising small and midsize biotech companies. During her time at Ferndale Advisors, Ms. Mikail co-founded two start-up companies, led various transformational business development and financing transactions and assisted in raising more than $50 million. Before founding Ferndale Advisors, Ms. Mikail was Chief Administrative Officer and Head of External Business Development/Alliance Management & General Counsel at Axovant Sciences, Inc., where she was an integral member of the team that raised $362 million in the company’s IPO. Prior to joining Axovant, Ms. Mikail held a variety of senior positions at NPS Pharmaceuticals, Inc., Dendreon Corporation, Eli Lilly and Company and ImClone Systems. Ms. Mikail developed her life sciences focus as a corporate and securities lawyer at Reed Smith and WilmerHale. Ms. Mikail graduated cum laude with a B.A. from Rutgers University, Rutgers College, New Brunswick, NJ, and earned a J.D. from Fordham University, School of Law, New York, NY.

Education

• J.D. Fordham School of Law (1999 — 2002)

Companies

• President Neurogene Inc. (2019)
• Principal Ferndale Advisors (2017)
• Adjunct Professor Rutgers Business School (2017)
• Co-Founder, Director and Chief Business Officer (part time) Neumentum, Inc. (2017 — 2019)
• Board Member Advanced Accelerator Applications (2017 — 2018)
• CAO, Head of External Business Development & GC Axovant Sciences (2015 — 2017)
• Senior Vice President, Legal Affairs, General Counsel and Secretary NPS Pharma (2014 — 2015)
• EVP, Corporate Development, GC & Secretary Dendreon (2012 — 2014)
• Senior Vice President, Corporate Development Savient Pharmaceuticals, Inc. (2011 — 2012)